Mariner LLC Sells 5,719 Shares of Hologic, Inc. (NASDAQ:HOLX)

Mariner LLC cut its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 14.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 33,484 shares of the medical equipment provider's stock after selling 5,719 shares during the period. Mariner LLC's holdings in Hologic were worth $2,414,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of HOLX. General Partner Inc. bought a new stake in Hologic in the fourth quarter valued at approximately $26,000. Venturi Wealth Management LLC raised its stake in Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after buying an additional 261 shares during the period. EverSource Wealth Advisors LLC raised its stake in Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after buying an additional 260 shares during the period. Smartleaf Asset Management LLC raised its stake in Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after buying an additional 159 shares during the period. Finally, Smithfield Trust Co raised its stake in Hologic by 160.0% in the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock valued at $45,000 after buying an additional 400 shares during the period. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Price Performance

HOLX traded up $0.06 on Monday, hitting $58.08. 1,579,266 shares of the stock were exchanged, compared to its average volume of 1,968,880. Hologic, Inc. has a 12 month low of $55.89 and a 12 month high of $84.67. The business has a 50-day moving average of $60.90 and a two-hundred day moving average of $69.77. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The firm has a market capitalization of $13.03 billion, a price-to-earnings ratio of 18.32, a PEG ratio of 2.14 and a beta of 0.82.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Sell-side analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have issued reports on HOLX shares. Leerink Partnrs lowered Hologic from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 6th. Royal Bank of Canada lowered their target price on Hologic from $88.00 to $85.00 and set a "sector perform" rating on the stock in a research note on Thursday, February 6th. Citigroup reduced their price target on Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Argus cut Hologic from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Finally, Stephens reissued an "overweight" rating and set a $84.00 target price on shares of Hologic in a report on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Hologic has an average rating of "Hold" and an average target price of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.